Daily Signals
2481 companies scored · 2026-10-14 run in progress: 3770 of ~5379 signals so far · Total · absolute moveSwitch to Alpha · 30D 90D
Distribution of the day's forecasts
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
287 companies
Sorted by market cap ↓ · forecast rankings are part of the paid plans
| Ticker | Rating | 90D | Δ | |
|---|---|---|---|---|
| XTLBXTL BIOPHARMACEUTICALS LTD | +2.57% | · | ||
| URGNUroGen Pharma Ltd. | Unlock rating and forecasts | |||
| XERSXeris Biopharma Holdings, Inc. | Unlock rating and forecasts | |||
| MLYSMineralys Therapeutics, Inc. | +2.91% | · | ||
| AGIOAGIOS PHARMACEUTICALS, INC. | +2.27% | · | ||
| VIRVir Biotechnology, Inc. | Unlock rating and forecasts | |||
| TRVITrevi Therapeutics, Inc. | Unlock rating and forecasts | |||
| XNCRXencor Inc | Unlock rating and forecasts | |||
| SRPTSarepta Therapeutics, Inc. | Unlock rating and forecasts | |||
| SEPNSepterna, Inc. | Unlock rating and forecasts | |||
| MRVIMARAVAI LIFESCIENCES HOLDINGS, INC. | Unlock rating and forecasts | |||
| NTLAIntellia Therapeutics, Inc. | Unlock rating and forecasts | |||
| NUVBNuvation Bio Inc. | Unlock rating and forecasts | |||
| ZBIOZenas BioPharma, Inc. | Unlock rating and forecasts | |||
| ANIPANI PHARMACEUTICALS INC | Unlock rating and forecasts | |||
| OCULOCULAR THERAPEUTIX, INC | +2.57% | · | ||
| GENBGenerate Biomedicines, Inc. | Unlock rating and forecasts | |||
| CMPSCOMPASS Pathways plc | Unlock rating and forecasts | |||
| ETONEton Pharmaceuticals, Inc. | +3.05% | · | ||
| INVAInnoviva, Inc. | Unlock rating and forecasts | |||
| PAHCPHIBRO ANIMAL HEALTH CORP | +2.51% | · | ||
| MAZEMaze Therapeutics, Inc. | Unlock rating and forecasts | |||
| RAREUltragenyx Pharmaceutical Inc. | Unlock rating and forecasts | |||
| STOKStoke Therapeutics, Inc. | Unlock rating and forecasts | |||
| PCRXPacira BioSciences, Inc. | Unlock rating and forecasts | |||
| CBIOGYRE THERAPEUTICS, INC. | Unlock rating and forecasts | |||
| IMCRImmunocore Holdings plc | +3.03% | · | ||
| RAPPRapport Therapeutics, Inc. | Unlock rating and forecasts | |||
| OMEROMEROS CORP | Unlock rating and forecasts | |||
| QUREuniQure N.V. | Unlock rating and forecasts | |||
| ANABANAPTYSBIO, INC | +3.05% | · | ||
| NKTRNEKTAR THERAPEUTICS | Unlock rating and forecasts | |||
| SNDXSyndax Pharmaceuticals Inc | Unlock rating and forecasts | |||
| GHRSGH Research PLC | Unlock rating and forecasts | |||
| TSHATaysha Gene Therapies, Inc. | Unlock rating and forecasts | |||
| REPLReplimune Group, Inc. | Unlock rating and forecasts | |||
| AMPHAmphastar Pharmaceuticals, Inc. | +2.35% | · | ||
| TYRATyra Biosciences, Inc. | Unlock rating and forecasts | |||
| OPKOPKO HEALTH, INC. | Unlock rating and forecasts | |||
| MNKDMANNKIND CORP | Unlock rating and forecasts | |||
| QDELQuidelOrtho Corp | Unlock rating and forecasts | |||
| MGTXMeiraGTx Holdings plc | +2.97% | · | ||
| IMTXImmatics N.V. | Unlock rating and forecasts | |||
| CGEMCullinan Therapeutics, Inc. | Unlock rating and forecasts | |||
| RIGLRIGEL PHARMACEUTICALS INC | Unlock rating and forecasts | |||
| ANROAlto Neuroscience, Inc. | Unlock rating and forecasts | |||
| CYRXCryoport, Inc. | Unlock rating and forecasts | |||
| ALMSALUMIS INC. | Unlock rating and forecasts | |||
| GLUEMonte Rosa Therapeutics, Inc. | Unlock rating and forecasts | |||
| ABUSArbutus Biopharma Corp | +3.16% | · | ||
By sector
Median 90D forecast per sector. Click to filter.
Rating changes
Unlock the full ranking
Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.
See plans Create a free accountRatings are relative: the forecasts of the latest complete daily run (2026-10-13) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.